Tesamorelin is a stabilized GHRH analogue studied for visceral fat reduction, GH pulsatility, and metabolic optimization. Physician-reviewed. Prescription required.
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone, designed to stimulate endogenous Growth Hormone secretion. It is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy, but its mechanism is similar to other GHRH analogs like CJC-1295.
Tesamorelin stimulates pulsatile GH secretion through GHRH receptor agonism, driving IGF-1 production and lipolytic effects on visceral adipose tissue. Its longer-acting design allows for sustained receptor stimulation. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| GHRH receptor agonism | Stimulates GH release |
| cAMP/PKA signaling | Drives pituitary hormone secretion |
| Amplified GH pulsatility | Physiologic hormone rhythm |
| IGF-1 production | Lipolysis and anabolic effects |
| Lipolytic effect on visceral fat | Reduced visceral adiposity |
| Long-acting design | Prolonged receptor stimulation |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with Tesamorelin protocol candidates in clinical practice:
Visceral Fat Reduction
Individuals with physician-confirmed visceral adiposity seeking GH-mediated metabolic support.
GH Optimization
Individuals with GH decline pursuing physician-supervised GHRH-based secretagogue therapy.
Metabolic Protocol
Individuals with metabolic syndrome components where GH axis support may be clinically appropriate.
Combination Stack
Patients combining tesamorelin with Ipamorelin or AOD-9604 under physician oversight.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
1–2 mg/day
Administration
Subcutaneous injection
Duration
12–26 weeks (physician-determined)
Frequency
Once daily (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.
Begin your Tesamorelin protocol.
Complete your intake. Physician review within 24–48 hours.
Physician-reviewed. Pharmacy-dispensed. Prescription required before any order is fulfilled.
Prescription required. Results may vary. Individual outcomes may differ.
Tesamorelin is FDA-approved for HIV-associated lipodystrophy and is used off-label for visceral fat reduction, growth hormone support, and body composition improvement.
Tesamorelin stimulates GH release, which promotes fat oxidation — particularly visceral (abdominal) fat. Clinical trials showed significant reduction in trunk fat compared to placebo.
Tesamorelin is often used as a long-term continuous protocol under physician monitoring. Short cycles of 3-6 months are also used for targeted body composition goals.
Yes. Tesamorelin is commonly stacked with ipamorelin or AOD-9604 for enhanced metabolic and fat-loss effects.